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Abstract
Cardiovascular (CV) diseases and mood disorders are common public health problems worldwide. Their connections are 
widely studied, and the role of neurotrophins (NTs) is already supposed in both conditions. However, data in the literature of 
clinical aspects are sometimes controversial and no reviews are available describing possible associations between CV risk 
and mood disorders based on NTs. The mostly studied NT is brain-derived neurotrophic factor (BDNF). Decreased level of 
BDNF is observed in depression and its connection to hypertension has also been demonstrated with affecting the arterial 
baroreceptors, renin–angiotensin system and endothelial nitric oxide synthase. BDNF was also found to be the predictor 
of CV outcome in different patient populations. Other types of human NT-s, such as nerve growth factor, neurotrophin 3 
and neurotrophin 4 also seem to have both psychopathological and CV connections. Our aim was to overview the present 
knowledge in this area, demonstrating a new aspect of the associations between mood disorders and CV diseases through 
the mediation of NTs. These findings might enlighten new psychosomatic connections and suggest new therapeutic targets 
that are beneficial both in respect of mood disorders and CV pathology.
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Introduction
Neurortophic factors or neurotrophins (NTs) consist a family 
of trophic factors of secreted proteins that promote growth, 
survival and differentiation of neurons both in the central 
and peripheral nervous system (Chao et  al. 2006). The 
members of the NT family are structurally similar proteins 
(Keefe et al. 2017), and in mammals comprise the follow-
ing four types: brain-derived neurotrophic factor (BDNF), 
nerve growth factor (NGF), neurotrophin 3 (NT-3), and 
neurotrophin 4 (NT-4) (Skaper 2008). The biological effects 
of mature NTs are mediated through the activation of one 
or more of the three tyrosine kinase receptors: tropomyosin 
receptor kinase A, -B, -C (TrkA, TrkB, TrkC). Neverthe-
less, NTs are synthesized from proneurotrophins, which are 
proteolytically cleaved to mature NTs. Proneurotrophins 
preferentially activate p75 neurotrophin receptor (p75Ntr) 
(Skaper 2008) and mainly induce apoptotic processes. The 
proneurotrophin cleavage seems to be an important factor, 
as the two classes of receptors (Trks and p75Ntr) interest-
ingly act antagonistically on many physiological functions 
(Tsai 2017).
Both transcriptional and posttranslational mechanisms are 
involved in upstream regulation of neurotrophins. Neurotro-
phins’ gene structure is very complex, contains several cod-
ing and non-coding exons with multiple promoters and vari-
ous spliced variants have also been reported. Human BDNF, 
for example, has a very complex gene structure, including 
11 non-coding exons that are spliced independently to form 
a coding exon, thus more than 15 mRNA transcripts can be 
produced (Pruunsild et al. 2007). There are several cis and 
trans-acting transcriptional elements as well, which regu-
late the promoters of neurotrophins, contributing to various 
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productions of neurotrophins. In neurons, cAMP response 
element binding protein (CREB) is one of the major tran-
scription factors and an important regulator of neurotro-
phins’ gene expression.
Other studies demonstrated that various neurotransmit-
ters, hormones and other neurotrophins also contribute 
to the transcriptional regulation of neurotrophins, but the 
molecular components involved in this regulation have not 
been clarified yet (Lindholm et al. 1994). Glutamate and ace-
tylcholine up-regulate NGF and BDNF mRNA expression, 
while GABA down-regulates the levels of NGF and BDNF 
(Zafra et al. 1990, 1991). The regulation of NT-3 production 
is independent of cholinergic neuronal activity (da Penha 
Berzaghi et al. 1993).
Posttranslational modifications are also important pro-
cesses regulating the productions of neurotrophins. Recently, 
a direct link between sigma-1 receptor (S1R) and BDNF has 
been discovered. Some studies described that S1R agonists 
(endogen like dehydroepiandrosterone or exogenous like 
SSRI fluvoxamine) increase BDNF expression and activate 
its downstream signaling. Others demonstrated that S1R 
acting as a chaperone protein enhances secretion of mature 
BDNF (Fujimoto et al. 2012). Our group also showed that 
S1R agonism by the fluvoxamine increases BDNF secretion 
in the rat hippocampus (Lenart et al. 2016).
Cardiovascular (CV) diseases are the leading cause of 
morbidity and mortality in most industrialized countries 
worldwide, despite highly effective preventive treatments. 
As CV diseases exert an excessive public health burden, 
exploring new pathophysiological pathways with the hope 
of new preventive and therapeutic potential can have an 
outmost importance. One of these new possibilities could 
be the involvement of NTs, which exert diverse effects on 
the developing and mature CV system. Their expression 
continues throughout life, influencing hypertension, ath-
erosclerosis, diabetes and myocardial ischemia (Emanueli 
et al. 2014).
Mood disorders are also common public health problems 
in the Western world and their strong connection with CV 
diseases is broadly recognized (Penninx et al. 2001). Lower 
NT concentrations, such as serum BDNF and NGF have 
been shown to correlate negatively with many affective dis-
orders including bipolar disorder (Barbosa et al. 2014; Lin 
et al. 2014), major depressive disorder (Brunoni et al. 2008), 
mania (Tramontina et al. 2009) and obsessive compulsive 
disorder (Maina et al. 2010). Although NTs themselves 
do not control mood directly, they are fundamental in the 
activity-dependent modulation of networks and changes in 
plasticity can affect mood as well (Castren et al. 2007).
As NTs can cross the blood–brain barrier, they potentially 
can influence CV pathology and psychopathology at the 
same time. BDNF is not only able to cross the blood–brain 
barrier (Pan et al. 1998), but in the periphery it is stored in 
platelets as well (Karege et al. 2002). Interestingly, while 
BDNF and NT-3 (as well as NT-4) are both structurally and 
functionally related to NGF (Maness et al. 1994; Sariola 
et al. 1994), the permeability coefficient-surface area of NGF 
is much lower compared with other NTs (Poduslo and Cur-
ran 1996).
Our aims are to overview the changes of NTs in psychi-
atric conditions and in CV diseases to demonstrate a new 
area of psychosomatic connections. We also aim to review 
the present knowledge about the therapeutic possibilities to 
restore the level of NTs and their consequences for different 
outcomes.
Brain‑derived neurotrophic factor (BDNF)
BDNF is the most frequently studied NT. It is initially syn-
thesized in the endoplasmic reticulum as its precursor pro-
tein, preproBDNF. After the cleavage of the signal peptide 
this form becomes proBDNF, and proBDNF is converted by 
extracellular proteases to mature BDNF (Ethell and Ethell 
2007; Yoshida et al. 2012).
Mature BDNF binds with higher-affinity Trk family 
receptors (Villanueva 2013)—especially TrkB—increas-
ing cell survival and differentiation, dendritic spine com-
plexity, long-term potentiation (Lu et al. 2008; Messaoudi 
et al. 2002), synaptic plasticity (Kang and Schuman 1996), 
and the resculpting of neuronal networks (Lee et al. 2001). 
ProBDNF is also biologically active, it mediates its actions 
through binding to low-affinity p75Ntr, having antagonistic 
effect compared to matured BDNF: reducing spine complex-
ity and density (Zagrebelsky et al. 2005) and promoting neu-
ronal cell death (Teng et al. 2005).
BDNF in mood disorders
Numerous clinical studies confirm the involvement of BDNF 
in the pathophysiology of depression (Lee and Kim 2010). 
Reductions in serum and plasma mature BDNF have been 
demonstrated in patients suffering from depression (Lee 
et al. 2007; Yoshida et al. 2012) and in those who com-
mitted suicide (Birkenhager et al. 2012; Kim et al. 2007b). 
Significantly lower levels of serum BDNF were found in 
antidepressant-free patients with major depressive disorder 
compared with healthy controls (Shimizu et al. 2003), which 
findings were confirmed by a large cohort study (Molendijk 
et al. 2011) and by three meta-analyses as well (Bocchio-
Chiavetto et al. 2010; Brunoni et al. 2008; Sen et al. 2008).
The regulatory background of BDNF in psychopathology 
is not totally clarified yet, but epigenetic mechanisms (chro-
matin remodeling, DNA methylation) have been implicated. 
Both in schizophrenia and in depression at the promoter I of 
BDNF DNA methylation at a specific CpG site is increased 
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resulting in reduced BDNF gene transcription (Fuchikami 
et al. 2011; Ikegame et al. 2013).
Single nucleotide polymorphism in BDNF gene is a plau-
sible candidate to be associated with the development of 
psychopathology. The Val66Met polymorphism is character-
ized by an amino acid substitution of valine (Val) to methio-
nine (Met) at amino acid residue 66. The presence of Met 
allele causes a failure in intracellular trafficking and pack-
aging of proBDNF, which results in a 25% reduction of the 
activity-dependent secretion of mature BDNF (Egan et al. 
2003). However, the role of Val66Met polymorphism in psy-
chiatric disorders is well studied but the results are incon-
sistent. Some studies reported that Met/Met patients have 
more severe symptoms of depression (Czira et al. 2012), 
whereas others showed that Val/Val genotype is associated 
with increased depressive symptoms (Jiang et al. 2013) or 
higher scores on the cognitive–affective factor of the Beck 
Depression Inventory-II test (Duncan et al. 2009).
BDNF and CV pathology
BDNF plays an important role during development of the 
CV system: it activates TrkB receptor leading to the survival 
of endothelial cells and the formation of the cardiac vascu-
lature (Emanueli et al. 2014). Embryonic BDNF deficiency 
impairs the development of intramyocardial vessels and can 
also lead to cardiac hypercontractility (Donovan et al. 2000). 
BDNF functions as an angiogenic regulator, promoting angi-
ogenesis (Kermani et al. 2005). It is expressed in a greater 
amount in the peripheral vessels, where it could influence 
vasoreactivity (Prigent-Tessier et al. 2013). BDNF is able 
to enhance vascular flow and can regulate revascularization 
of ischemic tissues (Kermani et al. 2005). Furthermore, it 
improves left-ventricular function in ischemic myocardium 
(Liu et al. 2006).
In CVD, the role of Val66Met polymorphism is still 
unclear, but interestingly in a follow-up clinical study 
patients carrying Met allele were associated with a reduced 
risk of clinical CVD events and lower severity of coronary 
artery disease than Val/Val genotype (Jiang et al. 2017). 
However, further investigations are needed to clarify the 
genetic aspect of the link between BDNF and CVD.
How can BDNF influence blood pressure, potentially 
playing an important role in the development of hyperten-
sion? Axonal guidance is among the top pathways explain-
ing the association between mood disorders and cardio-
metabolic-disease risk (Amare et al. 2017). Mutant axonal 
guidance genes—including BDNF—followed by abnormal 
axonal guidance and connectivity can cause disorders pri-
marily in the brain and subsequently in peripheral organs 
(Sasaki et  al. 2014). During embryonic development, 
BDNF is found to be a target-derived survival factor for a 
large subset of nodose ganglion neurons, such as arterial 
baroreceptors (Brady et al. 1999) and is also involved in the 
development of chemoafferent sensory neurons innervating 
the carotid body (Conover et al. 1995; Erickson et al. 1996). 
Furthermore, postnatally BDNF is expressed by the nodose 
ganglion neurons themselves (Schecterson and Bothwell 
1992; Wetmore and Olson 1995) and can be also released 
from these neurons by activity (Balkowiec and Katz 2000). 
BDNF is expressed in arterial baroreceptors and their central 
terminals in medial nucleus tractus solitarius in vivo. BDNF 
release from cultured nodose ganglion neurons is increased 
by electrical stimulation with patterns that mimic the in vivo 
activity of baroreceptor afferents (Martin et al. 2009). Thus 
it seems that BDNF is involved not only in the develop-
ment of baroreceptors, but also in their normal functioning 
in adulthood.
During normal conditions when blood pressure increases, 
the activated baroreflex reduces heart rate and blood pres-
sure by a negative feedback loop. In addition, elevated blood 
pressure activates inhibitory GABAergic neurons in the 
hypothalamus, reducing the secretion of the blood pressure-
elevating hormone vasopressin (Marosi and Mattson 2015). 
But different pathophysiological changes can influence the 
mechanism of the baroreflex loop. It is already shown that 
high dietary salt intake can affect blood pressure through 
NT-mediated changes of the central homeostatic circuit. 
Choe et al. proved in an animal study that chronic high salt 
intake is able to decrease the baroreceptor-mediated inhibi-
tion of vasopressin neurons through a BDNF-dependent acti-
vation of TrkB receptors and through the downregulation of 
potassium/chloride co-transporter 2 expression, which pre-
vents inhibitory of GABAergic signaling (Choe et al. 2015). 
Furthermore, reduced BDNF level in mice results in elevated 
heart rate, and infusion of this NT into the cerebral ventricles 
can restore this effect (Wan et al. 2014). In the same study, 
Wan et al. showed that GABAergic responses are increased 
in brainstem cardiovagal neurons of BDNF+/− mice, sug-
gesting that BDNF increases the activity of the parasym-
pathetic neurons to reduce heart rate (Wan et al. 2014). In 
summary, BDNF is required for normal carotid body inner-
vation, baroreceptor function and heart rate regulation and 
these effects can be blunted in pathological conditions, such 
as high salt intake, which can lead to the development of 
hypertension.
Another pathway explaining the association between 
BDNF, CV function and susceptibility to mental diseases 
as well is the renin–angiotensin system (RAS). Increased 
central RAS activation is an indicator of many CV diseases, 
such as hypertension and heart failure (Biancardi et al. 2014; 
Zucker et al. 2012). On the other hand, data are accumulat-
ing about the newly discovered effects of the RAS related to 
neuroprotection, cognition and cerebral vasodilation. Angio-
tensin (AT) 1–7 also affects non-CV functions in the brain, 
such as learning, memory, and neuroprotection (Farag et al. 
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2017). Clinical studies have shown that AT II receptor type 1 
(AT1R) blockers—independent of blood pressure-lowering 
effect—improve cognitive function in elderly hypertensive 
patients (Fogari et al. 2003; Hajjar et al. 2005). The back-
ground mechanism of this phenomenon was investigated in 
animal studies. Goel et al. showed the evidence that chronic 
neuroinflammation and memory impairment in hyperten-
sion—associated with increased apoptotic cell death and 
with amyloid beta deposition—can be prevented with can-
desartan treatment, suggesting partly to be explained by an 
increase of BDNF/CREB (cAMP response element binding 
protein) expression (Goel et al. 2017). Furthermore, the con-
nection between RAS and TrkB signaling is proven in vitro 
(Becker et al. 2015) and in vivo as well, as Becker et al. 
demonstrated the mediator role of BDNF-TrkB signaling on 
Ang II-induced mean blood pressure and renal sympathetic 
nerve activity elevation in male rats (Becker et al. 2017). 
Thus probably RAS blockers restore BDNF through TrkB 
signaling pathway.
Cumulating data suggest the connection between 
endothelial dysfunction and BDNF as well. In an animal 
study, the protecting effect of the AT1R blocker candesar-
tan after stroke was mediated by endothelial nitric oxide 
(NO) synthase and it was positively associated with BDNF 
expression (Alhusban et al. 2017). BDNF is probably indi-
rectly associated with the NO-system as BDNF is secreted 
by endothelial cells (Zoladz and Pilc 2010), it increases vas-
cular endothelial growth factor (VEGF) expression, which 
induces angiogenesis (Chen et al. 2005a; Lin et al. 2014) and 
VEGF also enhances the NO production of endothelial cells 
(Youn et al. 2009). The connection with endothelial dysfunc-
tion is also supported by the observation, that circulating 
BDNF level inversely correlates with vascular cell adhe-
sion molecule-1 (Lee et al. 2012), which is an accepted bio-
marker of endothelial dysfunction (Burger and Touyz 2012).
Numerous data are available about the association 
between BDNF and CV health. In general population, a sig-
nificant positive correlation was observed between plasma 
BDNF and diastolic blood pressure, and sexual differences 
were demonstrated in relation with different serum lipids 
(Golden et al. 2010). As it was a cross-sectional study, it is 
unclear if these associations observed are casual or elevated 
plasma BDNF represents a compensatory response of the 
disrupted lipid metabolism and hypertension, but the eleva-
tion of serum BDNF in hypertension was confirmed by our 
study as well (Nemcsik et al. 2016). Interestingly, in con-
trast, decreased endothelial BDNF expression was found 
in hypertension (Prigent-Tessier et al. 2013), so the source 
of higher BDNF serum and plasma levels in hyperten-
sion is probably not the endothelial cells. Increased BDNF 
expression was found in atherosclerotic coronary arteries 
in humans (Ejiri et al. 2005), and decreased plasma BDNF 
level was observed in patients with metabolic syndrome 
(Chaldakov et al. 2004), acute coronary syndrome (Lorgis 
et al. 2010; Manni et al. 2005) and in type 2 diabetes mellitus 
(Krabbe et al. 2007).
About obesity we found contradictory results in the litera-
ture. Previous studies showed that serum BDNF is generally 
lower in overweight and obese subjects (Celik Guzel et al. 
2014; Corripio et al. 2012; El-Gharbawy et al. 2006). In con-
trary, others showed elevated serum BDNF level in obesity 
(Roth et al. 2013). This phenomenon has been explained 
by the fact that BDNF is also regulated by leptin, therefore 
leptin resistance—as one of the obesity-associated factors—
shall be considered in future studies.
Serum BDNF level was diminished in smokers, compared 
to non-smokers (Bhang et al. 2010; Kim et al. 2007a). Fur-
thermore, BDNF levels in chronic smokers were increased 
after smoking cessation (30).
In patients with angina pectoris Jiang at al. found that 
plasma BDNF was inversely associated with triglyceride and 
low-density lipoprotein (LDL)-cholesterol, male sex and age, 
while it was correlated positively with high-density lipopro-
tein (HDL)-cholesterol. In this cohort, low plasma BDNF 
was an independent predictor of future coronary events and 
mortality (Jiang et al. 2011). The predictive role of BDNF 
for future CV events and mortality was confirmed by other 
studies as well. Higher seBDNF was found to be associated 
with decreased risk of CV morbidity and mortality (Kaess 
et al. 2015). On contrary, decreased serum BDNF was found 
to be associated with increased risk of incident stroke/TIA 
(Pikula et al. 2013). In summary, these results suggest that 
BDNF is compensatory elevated in CV pathology and the 
lack of this elevation bears propensity for poor outcome.
Direct psychosomatic connections of BDNF
Only a few studies are available evaluating the role of BDNF 
both in vascular and psychiatric conditions. Affective tem-
perament types (depressive, cyclothymic, hyperthymic, 
irritable and anxious) are subclinical, trait-related manifes-
tations and commonly the antecedents of minor and major 
mood disorders (Rihmer et al. 2010). We previously demon-
strated that in chronic hypertensive patients with dominant 
irritable, anxious, cyclothymic and depressive affective tem-
peraments, serum BDNF level was decreased compared with 
chronic hypertensive patients without dominant affective 
temperaments (Laszlo et al. 2015). In chronic hypertensive 
patients, hyperthymic temperament score was found to be 
associated positively with serum BDNF level (Nemcsik et al. 
2016). As hyperthymic temperament score was found to be 
inversely associated with coronary atherosclerosis (Nemcsik 
et al. 2017), it can be proposed that BDNF is a mediator of 
the protective effect of hyperthymic temperament in CV con-
ditions. But in hypertension the elevation of BDNF can also 
be an effect of medications as in a preliminary study after 
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3 months of antihypertensive therapy a tendency of BDNF 
increase was observed (Korosi et al. 2017). In this cohort, 
almost all patients did get the ACE-inhibitor perindopril, 
which, although only in the brain, but was demonstrated to 
influence BDNF (Ali et al. 2016).
Opportunities to restore BDNF level
Considering that BDNF is involved in CV physiology and 
through enhancing the neuroplasticity and neurogenesis, it 
increases the resistance of neurons to metabolic and excito-
toxic stress (Marosi and Mattson 2014) a new therapeutic 
target of mood and CV disorders could be the restoration 
of BDNF level.
Lifestyle changes like physical activity, such as running 
and other types of aerobic exercise (Engesser-Cesar et al. 
2007; Griffin et al. 2011) or calorie restriction (Marosi and 
Mattson 2014) could be cardioprotective through BDNF 
mediation.
Long-term treatment with various antidepressants can 
also normalize serum BDNF level (Duman and Monteggia 
2006; Sen et al. 2008). In animal studies, antidepressants, 
including selective serotonin reuptake inhibitors, selective 
norepinephrine reuptake inhibitors, and monoamine oxi-
dase inhibitors elevate BDNF mRNA level in hippocam-
pus (Huang et al. 2008). In psychiatry practice, BDNF level 
improvement can be evoked not only through medication, 
but also through electroconvulsive therapy (Brunoni et al. 
2014). In relation with the CV pharmacology, the AT1R 
blocker candesartan is proven to restore BDNF (Alhusban 
et al. 2017) and the ACE-inhibitor perindopril has beneficial 
effects as well (Ali et al. 2016), but interestingly in case 
of ramipril this feature seems to be missing (Krikov et al. 
2008). As we previously mentioned, RAS blockers probably 
restore BDNF through TrkB signaling pathway.
In the future, a possibility of BDNF restoration could 
be  the inhibition of its degradation. The mechanism of 
BDNF degradation is not well investigated, in the literature 
there are only few studies about this process. More than 25% 
of synthesized BDNF is depredated by lysosomes. Soluble 
sortilin is a main protein, which directs the trafficking of 
BDNF. Sortilin binds to sorting motif of BDNF and facili-
tates BDNF allocation to the late endosome; hereby sortilin 
rescues BDNF from lysosomal degradation. Until now no 
pharmacological option exists to inhibit the degradation of 
BDNF. Modifying sortilin either with increasing its level or 
its binding action would be options to increase total BDNF 
levels through its decreased targeting to the lysosome (Evans 
et al. 2011).
As there is no agent that would reduce BDNF degrada-
tion, direct receptor (TrkB) activation via ligands/agonists 
or mechanisms of increasing the BDNF level would be also 
appropriate therapeutic applications. Based on the listed 
psychopathological and CV effects of BDNF, such a medi-
cation can potentially be beneficial for both systems.
Nerve growth factor (NGF)
NGF is another important member of the NT family, pro-
duced mainly in the cortex, hippocampus, hypothalamus, 
but—like BDNF—it is also found in peripheral nervous and 
immune systems (Wiener et al. 2015). The adrenal gland 
also appears to be an important biological target of NGF 
(Alleva et al. 1993; Aloe et al. 1986), thus it could represent 
an intermediate station in the communication between cen-
tral nervous system structures and peripheral organs (Cirulli 
and Alleva 2009). The mature, active form of NGF descends 
from proteolytic cleavage of a precursor form proNGF, 
which also has important roles during development and in 
adult life, having both pro-apoptotic and neurotrophic prop-
erties (Fahnestock et al. 2004a, b). The biological action of 
NGF is mediated by two receptors: the high-affinity recep-
tor TrkA, and the low-affinity transmembrane glycoprotein 
receptor p75, that regulates signaling through TrkA (Huang 
and Reichardt 2003). Binding of NGF to p75Ntr activates 
additional signaling pathways: in the absence or reduced 
expression of coexpressed TrkA receptors on NGF-target 
cell apoptosis is triggered by NGF (Ebendal 1992; Huang 
and Reichardt 2003). Therefore, the effect of NGF on target 
cells depends on the ratio of these two receptors co-distrib-
uted on the cell surface (Micera et al. 2007).
NGF in mood disorders
Like BDNF, NGF seems to be negatively associated with 
depression and suicide. Clinical studies showed reduced 
level of NGF in patients with major depressive disorder 
compared with healthy controls (Diniz et al. 2013; Xiong 
et al. 2011), and a study with suicide victims showed also 
decreased NGF in the hippocampus (Banerjee et al. 2013). 
Comparing patients with major depressive disorder to such 
with major depressive disorder and additional suicide risk, 
Wiener et al. found no differences in NGF levels, but differ-
ences were found when comparing them to healthy controls 
(Wiener et al. 2015). Similarly, Dwivedi et al. found differ-
ences of NGF levels in the prefrontal cortex and in the hip-
pocampus only when comparing suicide victims with major 
depressive disorder and suicide victims with other psychi-
atric disorders to healthy controls, but not when comparing 
the two analyzed groups to each other (Dwivedi et al. 2005). 
On the contrary, in an elderly population, Ziegenhorn et al. 
did not confirm the influence of depression on serum NGF 
level (Ziegenhorn et al. 2007). Thus, it seems that NGF has 
an important role in the pathophysiology of mood disorders, 
but with aging this association can be attenuated.
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NGF and CV pathology
Additionally to neural growth effects, NGF was the first 
NT found to be involved in the postnatal angiogenesis with 
the mediation of TrkA receptors (Emanueli et al. 2014)—
although the mechanism of the angiogenic effects of NGF is 
not totally clarified yet. It is mediated either by a direct effect 
on vascular endothelial cells, or indirectly by influencing 
the action of other endogenous growth factors, for example, 
VEGF (Han et al. 2008; Nico et al. 2008). Asanome et al. 
showed in an animal study that the effects of NGF on vas-
cular maturation are mediated through perivascular nerves 
(Asanome et al. 2014). Among other NTs, the expressions of 
NGF and TrkA are both dramatically upregulated by arterial 
balloon injury in rats and during neointima formation their 
increased levels are maintained (Emanueli et al. 2014).
It is known since the 90s that in spontaneously hyperten-
sive rats the NGF secretion in the vessels is elevated (Spits-
bergen et al. 1998; Tuttle et al. 1995; Zettler and Rush 1993). 
It is associated with sympathetic hyperinnervation (Head 
1989; Spitsbergen et al. 1998), which seems to be mediated 
by altered signaling of vascular smooth muscle cells (Tut-
tle et al. 1995). Further studies also implicated increased 
expression of NGF in the vascular system as causing the 
development of sympathetic hyperinnervation resulting in 
hypertension (Emanueli et al. 2014). On the other hand, 
the activation of TrkA by NGF is also required for survival 
of the sympathetic and sensory neurons that innervate the 
heart (Emanueli et al. 2014). NGF can protect against post-
ischemic dysfunction of sympathetic coronary innerva-
tion (Abe et al. 1997) and ischemia–reperfusion-induced 
myocardial injury in animal studies (Hiltunen et al. 2001). 
Therefore, it seems that in animal models NGF provides 
Janus-faced features mediating in one way the development 
of hypertension, and on the other hand, protecting against 
ischemia-induced injuries.
Recent human studies have reported that NGF has impor-
tance in atherosclerosis and related disorders (Chaldakov 
et al. 2004; Donovan et al. 1995). NGF level in advanced 
atherosclerosis of the coronary wall was significantly lower 
than in controls and plasma level of NGF was reduced in 
patients with metabolic syndrome compared with con-
trols (Chaldakov et al. 2004). One of the possible ways for 
explaining the role of NGF in metabolic disorders is the 
fact that NGF upregulates the expression of LDL receptor-
related protein, which leads to a decreased level of LDL, 
and subsequently a lower probability of atherosclerosis 
(Bu et al. 1998). Another explanation is that NGF shares 
a striking structural homology with proinsulin (Mukherjee 
and Mukherjee 1982), increases glucose-induced insulin 
secretion (Hiriart et al. 2001) and exerts certain insulin-
like effects on lipid metabolism (Mukherjee and Mukher-
jee 1982; Ng and Wong 1985) and on energy homeostasis 
(Salton 2003). Taken together, the fact that plasma NGF 
level is reduced in chronic (Chaldakov et al. 2004) as well 
as in acute stages of human coronary atherosclerosis (Manni 
et al. 2005), suggests the role of NT deficiency in the patho-
physiology of atherosclerosis and the association of NGF 
with CV diseases (Manni et al. 2005).
Direct psychosomatic evidences of NGF
No human study is available evaluating both psychopatho-
logical and CV disease conditions in relation with the role 
of NGF. The administration of NGF in eye-drops in strep-
tozotocin-induced diabetic rats was proven to recover brain 
damage in the prefrontal cortex by activating protective and 
remodeling pathways triggered by BDNF. The authors also 
suggest based on their result that NGF-induced changes 
in BDNF signaling might influence the manifestation of 
depressive phenotype in diabetic rats (Rosso et al. 2017). 
These results suggest that the potentially beneficial psycho-
somatic effects of NGF are mediated by BDNF, but future 
studies are required to confirm this hypothesis.
Opportunities to restore NGF level
There are data in the literature that exercise can influence 
NGF. In soldiers, plasma NGF level was increased following 
emotional excitation and physical stress (Dugue et al. 1993; 
Schedlowski et al. 1993), and intense and prolonged physical 
exercise was associated with an increased serum NGF level 
in athletes (Bonini et al. 2013).
The therapeutic options for normalizing NGF levels are 
not that well known as in case of BDNF. Certain antide-
pressants—such as nortriptyline and citalopram—increased 
NGF levels in both experimental and clinical studies (Has-
sanzadeh and Rahimpour 2011). On the other hand, the 
decreased NGF level of patients with major depressive 
disorder decreased further after duloxetine administration 
(Martino et al. 2013). Interestingly, in another study after 
8 weeks of intensive administration of antidepressants, sig-
nificant improvement in the clinical symptoms of mood dis-
orders was demonstrated without changes in NGF level (Liu 
et al. 2014). These results suggest neutral or bidirectional 
response of NGF for different antidepressant agents.
Neurotrophin 3 (NT‑3)
Neither NT-3 nor its proform, proNT-3 have received as 
much attention in the literature as BDNF or NGF and their 
proforms. NT-3 binds mainly to TrkC receptors, but can also 
interact with less efficiency with TrkA and TrkB receptors 
(Yano et al. 2009). Like other NTs, NT-3 has an important 
role in the development and maintenance of the nervous 
system. It stimulates and controls neurogenesis through the 
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activation of TrkC receptors, plays role in the regulation 
of monoamine neurotransmitters such as noradrenaline and 
serotonin and enhances other neurotrophic factors such as 
BDNF and NGF (Pae et al. 2008). ProNT-3 exerts controver-
sial effects inducing cell death in superior cervical ganglion 
neurons through binding a complex between sortilin and 
p75Ntr (Gibon and Barker 2017).
NT‑3 in mood disorders
Studies about the possible connections between NT-3 and 
mood disorders are still controversial. Hock et al. found 
increased cerebrospinal fluid levels of NT-3 in elderly 
patients with depression compared with mentally healthy 
control subjects (Hock et al. 2000), and other studies also 
showed increased NT-3 level in bipolar disorders (Loch et al. 
2015; Tseng et al. 2016). In contrast, a study demonstrated 
the opposite result (Otsuki et al. 2008), while Munkholm 
et al. found no difference in NT-3 level in bipolar disorder 
patients compared with controls (Munkholm et al. 2014).
NT‑3 and CV pathology
NT-3 through TrkC activation is required for the develop-
ment of the ventricles, the atria and the cardiac outflow tracts 
(Donovan et al. 1996; Tessarollo et al. 1997). The lack of 
NT-3 leads to septal defects and Fallot tetralogy (Donovan 
et al. 1996).
While BDNF through TrkB activation is required for the 
survival of arterial baroreceptors during development (Brady 
et al. 1999), NT-3 is also involved in the development of 
chemoafferent sensory neurons innervating the carotid body 
(Conover et al. 1995; Erickson et al. 1996).
It is known that the NT-3 receptor TrkC is expressed in 
mouse skeletal muscle endothelial cells and also in human 
veins. Cristofaro et al. found in animal models that NT-3 
has a role in the stimulation of angiogenesis in which the 
endothelial NO synthase pathway has a critical role both 
in vivo and in vitro (Cristofaro et al. 2010).
Other studies suggest various effects of NT-3. Zhang et al. 
found elevated NT-3 level in hypertensive rat model com-
pared with normotensive animals (Zhang and Rush 2001). 
The presence of NT-3 in human arteriosclerotic lesions was 
also observed (Donovan et al. 1995) and this NT seems to 
be a profibrogenic mediator in human aortic valve: overpro-
duction of NT-3 by aortic valve tissue may contribute to the 
mechanism of valvular sclerosis (Yao et al. 2017).
Direct psychosomatic evidences of NT‑3
No animal or human study is available evaluating the role 
of NT-3 in psychopathology and CV pathology at the same 
time. As common pathophysiological pathways are present 
similarly like in the case of other NTs, the clarification of the 
possible psychosomatic role of NT-3 could be an interesting 
task of future studies.
Opportunities to restore NT‑3 levels
Similar to BDNF, NT-3 level can probably be restored with 
exercise: in animal model physical activity increased NT-3 
and TrkC expression following focal cerebral ischemia 
(Chung et al. 2017).
Currently, available findings suggest possible therapeutic 
implications of NT-3 in the treatment of depression (Pae 
et al. 2008). This can be explained with the fact that NT-3 
is a modulator of other NT-s, such as BDNF (Schutte et al. 
2000) and has a direct effect on monoamine neurotransmit-
ters such as 5-hydroxytryptamine and noradrenaline (Celada 
et al. 1996; Martin-Iverson et al. 1994).
Neurotrophin 4 (NT‑4)
Although NT-4 acts on the same TrkB receptor like BDNF, 
they do not invariably mediate the same effects (Hyman 
et al. 1994; Rodriguez Fermepin et al. 2009): BDNF elic-
its stronger and faster ubiquitination with TrkB than NT-4 
(Proenca et al. 2016), and NT-4 has a more potent effect 
than BDNF in the protection on striatal dopaminergic neu-
rons (Sauer et al. 1995). Little is known about proNT-4, but 
its truncated prodomain region prevents proNT-4 to bind 
to sortilin (Chen et al. 2005b). However, to date, its role in 
synaptic activity or synaptic plasticity has not been reported 
(Gibon and Barker 2017).
NT‑4 in mood disorders
NT-4 promotes survival and differentiation of hippocampal 
(Ip et al. 1992, 1993), noradrenergic (Friedman et al. 1993) 
and dopaminergic (Altar et al. 1994; Hyman et al. 1994) 
neurons. Striatal dopaminergic neurons are believed to be 
one of the key neurons in the pathophysiology of bipolar dis-
order (Sauer et al. 1995), thus the association between mood 
disorders and NT-4 level is probable, but the results are con-
troversial. Serum NT-4 was found to be elevated in patients 
with bipolar disorder compared with healthy controls (Tseng 
et al. 2016; Walz et al. 2009), however, in another study no 
differences were found between the two groups (Aydemir 
et al. 2014). Moreover, Barbosa et al. showed decreased 
NT-4 level in bipolar disorder with mania (Barbosa et al. 
2014).
NT‑4 and CV pathology
Similar to NT-3, NT-4 is also involved in the development 
of chemoafferent sensory neurons innervating the carotid 
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body (Conover et al. 1995; Erickson et al. 1996), and its 
presence in human arteriosclerotic lesions was also shown 
(Donovan et al. 1995).
As TrkB is a mediator of the long-term blood pressure 
and sympathetic nerve activity responses to central angio-
tensin II activity (Becker et al. 2017), NT-4—binding the 
same TrkB-receptor—might have similar functions, even if 
the role of NT4/TrkB signaling in sympathetic control of 
blood pressure is still even less precisely understood than 
BDNF/TrkB signaling.
Direct psychosomatic evidences of NT‑4
Similarly like NT-3, no animal or human studies are avail-
able evaluating the role of NT-4 in psychopathology and 
CV pathology at the same time. As NT-4 acts also on 
Fig. 1  Crossroads of neurotrophins in cardiovascular system and psy-
chopathology. Neurotrophin family consists four types of neurotro-
phins (NTs): nerve growth factor (NGF), brain-derived neurotrophic 
factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). 
NTs are synthesized as proforms that can be cleaved to release mature 
NTs. Both pro and mature forms of NTs are biologically active and 
eliciting opposite effects. ProNTs typically activate apoptotic down-
stream pathways via neurotrophin receptor p75 (p75Ntr). The effects 
of mature NTs are mediated by three tyrosine kinase receptors: NGF 
interacts with tropomyosin receptor kinase (Trk) A, BDNF binds to 
TrkB, NT-3 binds to TrkC and lower affinity to TrkA and TrkB (illus-
trated by gray dashed line) and NT-4 also interacts with TrkB. The 
effects of NTs on cardiovascular (CV) system: (i) NGF may have a 
protective role in atherosclerosis by upregulating LDL receptor-
related protein (LPR) and increasing glucose-induced insulin secre-
tion, while NT-4 and NT-3 seems to be a profibrotic mediator in aor-
tic valve. (ii) Both BDNF and NGF promote angiogenesis through 
vascular endothelial cells directly or by influencing the action of other 
endogenous factors indirectly. (iii) BDNF is required for the survival 
of arterial baroreceptors. NT-3 is involved in the development of che-
moafferent sensory neurons’ innervations of the carotid body. (iv) 
NGF promotes the survival of sympathetic and sensory neurons that 
innervate the heart. NT-3 promotes the development of the arteries 
and of the ventricles of the heart. The effects of NTs on mood dis-
orders: (i) BDNF and NGF participate in the pathophysiology of 
depression: reduced levels of NGF and BDNF in serum and also in 
plasma have been demonstrated in patients suffering from depression. 
(ii) Association between mood disorders and NT-3, NT-4 is plausi-
ble, but results are still controversial (illustrated by dashed narrows). 
Renin–angiotensin system (RAS) is one of the possible pathways 
might explaining the association between BDNF and CV function 
and susceptibility to mental disorders
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TrkB-receptor it might show similarities with the effects of 
BDNF, but the clarification of its exact role needs further 
studies.
Opportunities to restore NT‑4 levels
Little is known about the effect of different medications on 
NT-4 level. In a study of Loch et al. in patients with bipolar 
disorder after the administration of lithium, NT-4 level did 
not change (Loch et al. 2015). Apart from these results, no 
data are available in the literature about the possibilities of 
NT-4 level modification and its physiological consequences.
Conclusions
The accumulating data about the role of NTs, especially 
BDNF both in psychopathology and CV diseases, suggest 
that besides the involvement of the hypothalamic–pitui-
tary–adrenal axis and the autonomic nervous system, NT 
pathway can also mediate psychosomatic processes. Its 
physiological background is based on the shared signaling 
pathways descending from Trk receptors and p75Ntr to both 
psychopathological and CV directions. The summary of our 
knowledge in this field, which was detailed above in this 
manuscript is demonstrated in Fig. 1.
However, much more studies are needed, not only obser-
vational, but also interventional ones evaluating in psycho-
pathological and CV conditions at the same time aiming to 
discover the mediator role of NTs to confirm this hypothesis, 
but in case of supportive results, new therapeutic targets can 
be defined with the possibility of beneficial effects on two 
groups of diseases with huge public health impact.
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